Having trouble accessing articles? Reset your cache.

Vida seeking bigger deals, cures with $600M fund

With four liquidity events already from its first fund, Vida wants its second to deliver cures

As Vida Ventures prepares to deploy its $600 million second fund, the firm believes its larger investments in biotech megarounds can continue to be good bets.

Vida, whose team includes several former members of Kite Pharma Inc.’s management team, has already realized four liquidity events from its $255 million first fund, which closed in November 2017. One, the $372.6 million IPO of Allogene Inc. (NASDAQ:ALLO) in October 2018, followed

Read the full 689 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE